FDA Approves Biosimilar Pyzchiva® (ustekinumab-ttwe), to Be Commercialized by Sandoz in US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® (ustekinumab-ttwe) is approved by FDA for all indications of reference medicine FDA granted provisional determination for interchangeability designation for Pyzchiva® Extends Sandoz immunology portfolio and further strengthens biosimilar position Expected to be among first wave of ustekinumab biosimilars to launch in US [...]